来那度胺维持治疗进展的多发性骨髓瘤患者采用新型三联方案重新使用来那度胺治疗的结果 - Suppr | 超能文献

相似文献

1

Outcomes of lenalidomide retreatment with novel triplet regimens in patients with multiple myeloma progressing on lenalidomide-based maintenance therapy.来那度胺维持治疗进展的多发性骨髓瘤患者采用新型三联方案重新使用来那度胺治疗的结果

Br J Haematol. 2021 May;193(3):e23-e26. doi: 10.1111/bjh.17393. Epub 2021 Mar 21.

2

Real-world outcomes of maintenance therapy post-autologous stem cell transplantation in newly diagnosed multiple myeloma.新诊断多发性骨髓瘤自体干细胞移植后维持治疗的真实世界疗效

BMC Cancer. 2025 Feb 5;25(1):204. doi: 10.1186/s12885-025-13518-0.

3

Lenalidomide and Vorinostat Maintenance after Autologous Transplantation in Multiple Myeloma: Long- Term Follow-Up.来那度胺与伏立诺他在多发性骨髓瘤自体移植后的维持治疗：长期随访

Biol Blood Marrow Transplant. 2020 Jan;26(1):44-49. doi: 10.1016/j.bbmt.2019.09.005. Epub 2019 Sep 10.

4

RVD induction and autologous stem cell transplantation followed by lenalidomide maintenance in newly diagnosed multiple myeloma: a phase 2 study of the Finnish Myeloma Group.初诊多发性骨髓瘤患者采用来那度胺维持治疗的 RVD 诱导和自体干细胞移植：芬兰骨髓瘤研究组的 2 期研究。

Ann Hematol. 2019 Dec;98(12):2781-2792. doi: 10.1007/s00277-019-03815-7. Epub 2019 Oct 31.

5

Prolonged survival with increasing duration of lenalidomide maintenance after autologous transplant for multiple myeloma.多发性骨髓瘤自体移植后，来那度胺维持治疗持续时间延长可带来更长生存期。

Leuk Lymphoma. 2019 Feb;60(2):511-514. doi: 10.1080/10428194.2018.1473577. Epub 2019 Jan 8.

6

Isatuximab, bortezomib, lenalidomide, and limited dexamethasone in patients with transplant-ineligible multiple myeloma (REST): a multicentre, single-arm, phase 2 trial.isatuximab、硼替佐米、来那度胺与小剂量地塞米松用于不适宜移植的多发性骨髓瘤患者（REST）：一项多中心、单臂、2期试验

Lancet Haematol. 2025 Feb;12(2):e120-e127. doi: 10.1016/S2352-3026(24)00347-8.

7

Daratumumab with lenalidomide as maintenance after transplant in newly diagnosed multiple myeloma: the AURIGA study.达雷妥尤单抗联合来那度胺用于新诊断多发性骨髓瘤移植后维持治疗：AURIGA研究

Blood. 2025 Jan 16;145(3):300-310. doi: 10.1182/blood.2024025746.

8

The impact of lenalidomide maintenance on second-line chemotherapy in transplant eligible patients with multiple myeloma.来那度胺维持治疗对适合移植的多发性骨髓瘤患者二线化疗的影响。

Eur J Haematol. 2021 May;106(5):673-681. doi: 10.1111/ejh.13596. Epub 2021 Feb 16.

9

Post-transplant consolidation plus lenalidomide maintenance vs lenalidomide maintenance alone in multiple myeloma: A systematic review.移植后巩固联合来那度胺维持治疗与来那度胺单药维持治疗多发性骨髓瘤的系统评价。

Eur J Haematol. 2017 Dec;99(6):479-488. doi: 10.1111/ejh.12961. Epub 2017 Oct 6.

10

Vitiligo Following Autologous Hematopoietic Stem Cell Transplantation.自体造血干细胞移植后出现的白癜风

Clin Lymphoma Myeloma Leuk. 2020 Apr;20(4):e171-e173. doi: 10.1016/j.clml.2019.12.025. Epub 2020 Jan 9.

引用本文的文献

1

Retreatment of multiple myeloma with previously refractory drugs.使用先前难治性药物对多发性骨髓瘤进行再治疗。

Blood Adv. 2024 Dec 24;8(24):6321-6328. doi: 10.1182/bloodadvances.2024014723.

2

IMiD-Free Interval and IMiDs Sequence: Which Strategy Is Better Suited for Lenalidomide-Refractory Myeloma?无免疫调节药物（IMiD）间期与IMiD用药顺序：哪种策略更适合来那度胺难治性骨髓瘤？

Life (Basel). 2023 Nov 20;13(11):2229. doi: 10.3390/life13112229.

3

Efficacy of Daratumumab-Containing Regimens Among Patients With Multiple Myeloma Progressing on Lenalidomide Maintenance: Retrospective Analysis.